The lysosomal system is up-regulated in the brain of patients with Alzheimer's Disease (AD), as demonstrated by previous experiments carried out in post-mortem samples of brain patients. In this paper we provide evidence that an up-regulation of lysosomal glycohydrolases (α-D-mannosidase, β-D-hexosaminidase and β-Dgalactosidase) takes place in skin fibroblasts from AD patients affected either by sporadic or familial forms and is detectable also in pre-symptomatic subjects carrying the above mutations but healthy at the time of skin biopsy. This increase of enzyme activity is consequent to a transcriptional up-regulation. The oncogene ras appears to be involved in the regulation of enzymatic activity. A parallel increase of ras transcript and ras protein, without an increase of p44/p42 MAPK activation was revealed in the same AD fibroblasts.
INTRODUCTION
Alzheimer's Disease is the most common cause of dementia in the elderly. Very little is known about the causes of AD, except that its end stages involve extensive neuronal loss and the appearance of distinctive neuropathological features. A certain proportion of AD cases (~ 10%) appears to be related to mutations in the β-amyloid precursor protein (APP) gene or the presenilin genes PS1 and PS2 (1) (2) (3) , and information about AD pathogenesis arise mainly from the study of these genetically transmitted forms.
events also found in age-related neurodegenerative diseases including AD and related tauopathies (10) . The endosomal-lysosomal pathway consists of a dynamic system of organelles working to recycle cellular ingredients, thereby providing a constant supply of basic components necessary to maintain the health of the cell. Lysosomes contain over 80 hydrolytic enzymes including acidic glycohydrolases and although they are considered to be a terminal degradative compartment for turning over and recycling cellular constituents, lysosomal enzyme activities may carry out limited hydrolysis to generate new functionally important substrates.
During early stages of AD, a variety of growth factors and mitogenic compounds are elevated (11) (12) (13) . Most of these factors mediate their cellular effects through activation of ras-dependent mitogen-activated protein kinase (MAPK) cascade, a pathway that is also involved in the regulation of expression and post-translational modification of the APP and tau proteins (14) (15) (16) . Previous studies demonstrated that ras expression in the frontal cortex of AD patients is elevated in early stages of the disease (17) . On the other hand, there are also evidences that ras alters the processing and subcellular localisation of the lysosomal protease cathepsin D (18) .
Current knowledge on lysosomal dysfunction or on signalling pathways alteration on AD arises from studies on post-mortem brain of AD patients or in FAD animal models.
In this report we carried out an investigation at peripheral level. We used as cell models fibroblast cell lines established from FAD patients, mutated on PS1, PS2 or APP genes; pre-symptomatic subjects (carrying the mutation but healthy at the time of skin biopsy); sporadic AD cases (SAD). As controls, we included non-AD demented patients, healthy subjects tested for absence of the above mutations and matched for demographic characteristics, and centenarians unaffected by significant cognitive impairment. We investigated on lysosomal glycohydrolases β-D-hexosaminidase (E.C. 3.2.1.52), β-Dgalactosidase (E.C. 3.2.1.23) and α-D-mannosidase (E.C.3.2.1.24) expression and demonstrated that they are up-regulated in fibroblasts from AD patients and that their expression is regulated by ras. The proteins were transferred to nitrocellulose membrane at 100 V for 1 h. The membrane was blocked by 5% non fat dry milk in Tris buffer saline with 0,1% Tween 20 (TBST) at RT for 1 h. Mouse monoclonal anti ras antibody, 1/500 diluted, was incubated overnight at 4 0 C. Rabbit polyclonal anti: P-p38 MAPK, p38 MAPK , P-p44/42 MAPK and p44/42 MAPK antibodies,1/1000 diluted, were incubated overnight at 4 0 C. As internal control, the membrane was also probed 1h at RT with mouse monoclonal anti β-tubulin antibody.
EXPERIMENTAL PROCEDURES Materials
Goat anti-mouse HRP-linked and goat anti-rabbit HRP-linked secondary antibodies were used according to manufacturer. Western Blotting were detected by chemiluminescence using either LumiGLO chemiluminescent reagent or p-coumaric acid and luminol .
RasV12 expression
Fibroblasts were infected with a pBABE-PURO retrovirus containing rasV12 or with control pBABE-PURO (produced by CaCl 2 transfection of Phoenix packaging cell line), then cultured for seven days under puromycin selection (1 µg/ml). Cell extracts, enzymatic activities, RNA purification and cDNA synthesis were performed as described.
Statistical analysis
The statistical significance of the difference between individual values of levels of glycohydrolases activity in fibroblasts from AD patients and from control subjects was evaluated using the Student's two-tailed unpaired t-test. The statistical significance between the same samples was also evaluated by ANOVA measures of variance.
RESULTS

Levels of glycohydrolases activity in fibroblasts from AD patients.
Specific activity of the glycohydrolases α-D-mannosidase, β-D-hexosaminidase and β-D-galactosidase, were measured in fibroblast cell extracts from FAD patients carrying a mutation in the PS1, PS2 or APP genes as well as in pre-symptomatic subjects from the same families; from SAD patients; from healthy subjects matched for age and sex, from patients affected by non-AD dementia and from centenarians. Characteristics of all patients and controls considered in this study are reported in Table 1 . All the PS1 mutated patients considered had an early onset of the disease and a robust accumulation of Aβ peptide in the brain. All SAD patients considered were strongly affected by the disease at the time of the skin biopsy. Subjects identified as pre-symptomatic at the time of skin biopsy, all developed the disease two-three years later on. Fig.1 shows the levels of activity detected. As evident from the figure, the expression of the three glycohydrolases is increased to a different extent in patients and pre symptomatic subjects. Five out of six PS1 FAD patients and six out six PS1 mutated pre-symptomatic subjects, displayed significant increases of α-D-mannosidase activity (p never < than 0.05); all patients and four out of six pre-symptomatic subjects carrying the PS1 mutation showed significantly high levels of β-hexosaminidase activity; five out six patients and only one out six presymptomatic subjects showed significantly high levels of β-D-galactosidase activity. the activities characterising the Golgi compartment or the ER-associated forms were also detectable. Similar results were obtained by using citrate-phosphate buffer (data not shown). As evident from the figure, in FAD patients the lysosomal form, and to a lesser extent the RE-associated form were increased, whereas no significant differences between controls and patients were found for the neutral form. In SAD fibroblasts the activity of all forms, including the neutral one, were increased.
Evaluation of lysosomal α-D-mannosidase and ras transcripts in FAD and SAD patient and control fibroblasts.
Levels of transcript for acidic α-D-mannosidase were evaluated by RT-PCR in all fibroblast populations previously analysed for their activity content. Data concerning PS1 mutated fibroblasts (symptomatic and pre-symptomatic) and some controls are reported in Fig. 3 , panel a; those concerning PS2-and APP-mutations, SAD and further controls are reported in Fig. 3 , panel c. Levels of ras transcripts were also evaluated using RT-PCR in the same fibroblasts populations (Fig. 3 , panels a and c). We used primers which allowed us to amplify a cDNA fragment (0.235 kb) shared by all multiple forms of ras.
Quantification of transcripts by densitometric analysis is reported in Fig. 3 
Evaluation of ras protein levels and MAPKs (p44/42 and p38) phosphorylation
To investigate the involvement of the ras signalling pathway in the up-regulation of lysosomal glycohydrolases activity, we measured the level of ras proteins and the extent of MAPKs activation in representative FAD and SAD fibroblast populations. We found an increase of ras protein, particularly strong in PS1 FAD and in SAD patients. (Fig. 4) . We then analysed the activation of the ras signalling pathway by measuring the extent of p44/42 MAPK phosphorylation (Fig. 4) . We didn't find significant differences in p44/p42
MAPK phosphorylation in control and AD fibroblasts. Considering that the activation of p38 MAPK is often correlated with neuronal degeneration (21, 22) and that recently it has been shown to occur in neurodegenerative diseases such as Alzheimer's and other taurelated diseases (23-25), we also investigated the degree of p38 MAPK activation (Fig.4) .
p38 MAPK was clearly activated, as demonstrated by the presence of the P-p38 MAPK band only in AD fibroblasts, both FAD and SAD cases, but not in controls.
Involvement of the ras signalling pathway in the up-regulation of lysosomal glycohydrolases activity.
In order to investigate the role of ras as upstream activator of lysosomal glycohydrolases, we induced normal fibroblasts or fibroblasts established from AD patients to overexpress an active form of ras by infecting them with a retroviral vector expressing a mutant ras (rasV12) (26). As control we used the same fibroblasts infected with the empty vector. Results are reported in Fig. 5 and show a significant increase of α- Age-related lysosomal perturbation has been previously suggested to prompt pathogenic fibril formation and intracellular deposits of amyloidogenic species in AD brains (27,28).
Alternative processing pathways through lysosomes were identified that potentially contribute to the production of amyloidogenic polypeptides (29-36).
Lysosomal Storage Diseases (LSDs) are due to mutations on genes encoding for is also evident in pre-symptomatic subjects, two-three years before the onset, so that it should be considered an early event in the pathogenesis of AD.
We further focused our attention on α-D-mannosidase activity. Mannosidases are a complex enzyme system involved in both the biosynthesis and catabolism of N-linked glycoproteins (20) and their involvement in the biosynthesis of APP has been described (16) . We first surveyed the overall forms of α-D-mannosidase in fibroblasts from AD patients and controls by evaluating the enzymatic activity at different pH values. From this analysis it emerges that the lysosomal acidic α-D-mannosidase was the form which displayed the highest increase in all AD fibroblasts analysed; the pH 5.5-6.0, Golgi located form was also increased in all AD fibroblasts, but to a lesser extent, whereas the neutral, Endoplasmic Reticulum associated form, was increased only in PS1 mutated and SAD- None of the mutations considered in this study seems to have a relevant or specific role in this up-regulation, which occurs in almost all AD fibroblasts, independently if they were established from FAD or SAD patients. The ApoE phenotypes were also considered but they were not significantly different within the various groups of patients.
Our overall results are more consistent with the hypothesis of a lysosomal model of Further studies on ras pathway, and particularly on factors influencing p38 activation, may provide useful information for the identification of specific events involved in AD pathogenesis.
There are evidences that ras and the related rab proteins participate in the vesicular transport process required for normal trafficking of lysosomal enzymes, and there is a link between ras and the altered expression and subcellular distribution of lysosomal proteases such as cathepsins (18, 45, 46) or between ras and lysosomal dysfunction (47) . We here provide the direct evidence that ras activation is at the basis of lysosomal glycohydrolases up-regulation. In fact, when normal or AD fibroblasts were induced to express high levels of constitutively active ras, they displayed a considerable increase of glycohydrolases activity and levels of α-D-mannosidase transcript with respect to controls (cells transformed with the empty vector). This was true for normal, SAD or FAD fibroblasts, and represents the first direct evidence for an involvement of ras in glycohydrolases gene regulation. In addition it explains the molecular mechanism at the basis of glycohydrolases up-regulation in AD fibroblasts.
All the above observations arise from the analysis of fibroblast from skin biopsy of AD patients. Studies on fibroblasts from patients with neurological disorders have been previously carried out and revealed a wealth of information on how such disorders occur (48, 49) . Our data provide the evidence that fibroblasts are a good and easy peripheral source for studying molecular basis of AD, including early events taking place before the onset of the disease. Enzymatic changes detected in this study and ras activation might both be related to the pathogenesis of the disease and also be considered a potential peripheral diagnostic marker. 
FIG. 4
Western blot analysis of ras, p44/42 MAPK and p38 MAPKs. Panels a: Cell extracts from controls (5LS and C33) and AD fibroblasts (VNOV for PS1, 14UDS for PS2, UANSE for APP and NICC for SAD) were sized by SDS-PAGE and blotted as described.
The membrane was probed with the mouse monoclonal anti-ras, stripped and re-probed with anti-p44/42MAPK, anti-P-p44/42 MAPK, anti-p38 anti-P-p38. As internal control, 
